Although IBD is more common in non-Hispanic Whites compared to other racial groups, there is a disproportionately higher ratio of hospitalizations, surgery, and IBD-related mortality among non-Hispanic African Americans compared with other racial groups. This fact, in addition to the rising prevalence of IBD in North America and the estimate that 54% of the U.S. population will be comprised of minority populations by 2050, underscores the need for high-quality treatment available to racial and ethnic minority groups.
In this CMEOCast podcast, expert faculty discuss variations in IBD presentation in different racial groups, disparities in health care use, and approaches to mitigate inequality.
At the end of this CME/CE activity, participants should be able to initiate multidisciplinary collaboration to provide medically underserved children, adolescents, and adults with IBD with guideline-recommended care.
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.
Physicians, nurse practitioners, PAs, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Clarke reports that he is on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-007-H01-P
Call us at (877) CME-PROS or (877) 263-7767.